2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson et al.
The unmet need in DLBCL
Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL
What’s next for rare myelomas?
The latest data in diffuse large B-cell lymphoma from ICML 2017